Back to Treatments

Treatment

Immunotherapy (PD-1 Inhibitors e.g., Pembrolizumab/Nivolumab)

1
Conditions
20
Trials
1,000
Participants
60%
Average Safety

Condition Evidence

Malignant neoplasm of bone and articular cartilage

20 trials · 1,000 participants

40% effectiveness · 60% safety
Immunotherapy (PD-1 Inhibitors e.g., Pembrolizumab/Nivolumab) | DFDA